Clinical trial · no report yet · Phase 3
TROPION-Breast03
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
- NCT05629585 ↗
- Active, not recruiting
- AstraZeneca
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 17 | |
| Podcasts | 16 | |
| X threads | 5 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- Dato-DXd; Durvalumab; Capecitabine; Pembrolizumab
- Arms
- Dato-DXd in combination with Durvalumab · Experimental
- Dato-DXd · Experimental
- Investigators Choice Therapy · Active comparator
- Enrollment
- 1,174
- Primary outcomes
- Invasive disease-free survival (iDFS) for Dato-DXd + durvalumab vs. ICT
- Sponsor
- AstraZeneca with Daiichi Sankyo, SWOG Clinical Trials Partnerships, LLC
- Start
- Nov 28, 2022
- Primary completion
- Sep 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05629585 · updated Oct 14, 2026
Publications
linked from the registry- Bardia A, Pusztai L, Albain K, Ciruelos EM, Im SA, Hershman D, Kalinsky K, Isaacs C, Loirat D, Testa L, Tokunaga E, Wu J, Dry H, Barlow W, Kozarski R, Maxwell M, Harbeck N, Sharma P. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan +/- durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol. 2024 Apr 29;16:17588359241248336. doi: 10.1177/17588359241248336. eCollection 2024. PubMed 38686016